Reuters: Regulatory News: German regulator sees no new risks from Bayer's Xarelto

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

The Best Way to Manage your Money. Start using Mint today to set a budget, track your goals and do more with your money. From our sponsors

German regulator sees no new risks from Bayer's Xarelto Sep 9th 2013, 12:39 FRANKFURT, Sept 9 | Mon Sep 9, 2013 8:39am EDT FRANKFURT, Sept 9 (Reuters) - The number of reported side effects linked to Bayer's stroke prevention pill Xarelto is below worrisome levels, a German drugs regulator said, responding to a media report highlighting risks from taking the blood thinning drug. "There is no new risk situation," a spokesman for Germany's Federal Institute for Drugs and Medical Devices (BfArM) said on Monday. German magazine Der Spiegel reported over the weekend that Bayer faced a growing number of reports of bleeding in patients taking Xarelto, citing BfArM figures. Bayer shares had declined 1.7 percent by 1208 GMT, while Germany's blue-chip index DAX was little changed. "Xarelto is a major drug hopeful for Bayer and it's not good if a shadow is cast over it," said NordLB-analyst Thorsten Strauss. Bayer won regulatory approval in Europe for the drug's main use, preventing strokes in patients suffering from a common form of irregular heart beat, in December 2011. There were 968 cases of suspected undesirable side-effects related to Xarelto in the first eight months of 2013, including 72 deaths, the magazine reported. BfArM said that, while the figures were within a range that was to be expected, the regulator would continue to monitor reported side effects. A spokesman for Bayer said Xarelto's risk-benefit profile was still intact. Jointly developed with U.S. peer Johnson & Johnson, Xarelto is one of Bayer's most important new drugs, expected to yield annual peak sales of more than 2 billion euros ($2.63 billion). The stroke preventer, which is also used to treat and prevent deep vein thrombosis and pulmonary embolisms, competes with Eliquis, sold by Pfizer and Bristol-Myers Squibb , and with Boehringer Ingelheim's Pradaxa. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions